Shanghai Innostar Biotechnology Valuation

Is 688710 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688710 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688710's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688710's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688710?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 688710. This is calculated by dividing 688710's market cap by their current preferred multiple.
What is 688710's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥3.48b

688710 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	11.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 688710's PE Ratio compare to its peers?

The above table shows the PE ratio for 688710 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	35.7x
688621 Beijing Sun-Novo Pharmaceutical Research	17x	28.1%	CN¥3.7b
688222 HitGen	82.5x	20.1%	CN¥3.7b
301333 R&G PharmaStudies	28.9x	26.7%	CN¥3.9b
301096 Hangzhou Bio-Sincerity Pharma-TechLtd	14.2x	28.7%	CN¥4.1b
688710 Shanghai Innostar Biotechnology	19.7x	n/a	CN¥3.5b

Price-To-Earnings vs Peers: 688710 is good value based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (35.7x).

Price to Earnings Ratio vs Industry

How does 688710's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 688710 is good value based on its Price-To-Earnings Ratio (19.7x) compared to the Asian Life Sciences industry average (28.2x).

Price to Earnings Ratio vs Fair Ratio

What is 688710's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688710 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688710's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.